Compare Amylx Pharmaceuticals Inc (AMLX) vs Emerson Electric Co. (EMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Emerson Electric Co. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.06 (market cap $1.98B), while Emerson Electric Co. trades at $138.15 (market cap $77.79B). The key difference: Emerson Electric Co. is far larger — about 39.3× Amylx Pharmaceuticals Inc's market cap, and Emerson Electric Co. pays a 1.6% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | EMR | |
|---|---|---|
Market Cap | $1.98B | $77.79B |
Sector | Health | Industrials |
52-Week High | $18.70 | $161.69 |
52-Week Low | $7.64 | $123.30 |
Enterprise Value | $1.70B | $90.05B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Emerson Electric (EMR) trades at $138.88, up 0.78% today, with a bearish technical signal from moving averages. The stock shows stable revenue growth, with 2025 revenue of $18.02B and net income of $2.29B, supported by a strong gross profit margin of 52.67%. Recent news highlights investor attention and collaboration with Aramco on corrosion R&D, while the Intelligent Devices segment gains momentum.
EMR presents a mixed outlook: analyst consensus is bullish with a $157.60 price target, but technical indicators suggest near-term pressure. Key risks include volatile cash flows and competitive pressures in manufacturing electronics. The stock's valuation at a P/E of 32.15 may limit upside unless earnings accelerate.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Emerson Electric Co.
Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →
